US29337E1029
US29337E1029
Enliven Therapeutics, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | -- | -- | -- |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| 119.658.000 | 104.554.000 | 14.4% | |
| Operating Income | -119.658.000 | -104.554.000 | 14.4% |
| Pretax Income | -103.694.000 | -88.792.000 | 16.8% |
| Net Income Common Stockholders | -103.694.000 | -89.024.000 | 16.5% |
| -- | -- | -- | |
| -- | -- | -- |